Narita, Japan

Fumio Fukui

This inventor holds 2 USPTO granted patents. Top assignees: Showa Sangyo Co., Ltd., Agency of Industrial Science and Technology. Active years: 1988-1993.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 24(Granted Patents)


Location History:

  • Naritashi, JP (1988)
  • Narita, JP (1993)

Company Filing History:


Years Active: 1988-1993

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Fumio Fukui: Innovator in Biochemistry

Introduction

Fumio Fukui is a notable inventor based in Narita, Japan. He has made significant contributions to the field of biochemistry, particularly in the development of oligopeptides and their applications in health.

Latest Patents

Fumio Fukui holds 2 patents that focus on various oligopeptides and their therapeutic uses. His latest patents include compounds such as angiotensin converting enzyme inhibitors and hypotensive agents, which are derived from corn protein α-zein. These compounds include L-Tyr-L-Val, L-Leu-L-Tyr, L-Leu-L-Pro, L-Phe-L-Tyr, L-Tyr-L-Arg, and several others. Additionally, he has developed a method for promoting the proliferation of intestinal bifidobacteria using isomalto-oligosaccharides.

Career Highlights

Throughout his career, Fumio Fukui has worked with prominent organizations such as Showa Sangyo Co., Ltd. and the Agency of Industrial Science and Technology. His work has been instrumental in advancing the understanding of oligopeptides and their health benefits.

Collaborations

Fumio Fukui has collaborated with notable colleagues, including Susumu Maruyama and Hideoki Tanaka. These partnerships have contributed to his innovative research and development efforts.

Conclusion

Fumio Fukui's contributions to biochemistry and his innovative patents highlight his role as a significant inventor in the field. His work continues to influence advancements in health-related applications of oligopeptides.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…